NCT05232110|Unknown
Compassionate Use of Pozelimab
1 other identifier
R3918-Pozelimab
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredFeb 2022
Brief Summary
Provide compassionate use of pozelimab
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 28, 2022
Completed12 days until next milestone
First Posted
Study publicly available on registry
February 9, 2022
CompletedLast Updated
November 10, 2025
Status Verified
November 1, 2025
First QC Date
January 28, 2022
Last Update Submit
November 5, 2025
Conditions
Keywords
Complement Hyperactivation, Angiopathic thrombosis, Protein-Losing Enteropathy (CHAPLE disease)
Interventions
PozelimabDRUG
Also known as: REGN3918
Eligibility Criteria
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Protein-Losing Enteropathies
Condition Hierarchy (Ancestors)
Intestinal DiseasesGastrointestinal DiseasesDigestive System Diseases
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 28, 2022
First Posted
February 9, 2022
Last Updated
November 10, 2025
Record last verified: 2025-11